Mitochondrial Composition for Angiogenesis Without Stem Cell Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for safe and efficient methods to induce angiogenesis, particularly for treating ischemia-related diseases such as critical limb ischemia, peripheral artery disease, and myocardial infarction, as existing treatments face challenges like reduced angiogenic potential in aged patients, adverse effects from bone marrow extraction, and risks associated with stem cell therapy.
Innovation Solution
Administration of partially purified intact mitochondria or ruptured mitochondria, which have undergone at least one freeze-thaw cycle, to induce angiogenesis in tissues, enhancing blood flow and treating pathologies that benefit from angiogenesis, such as ischemic vascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If stem cell therapy is used to induce angiogenesis, then angiogenic potential is improved, but risks such as inflammation, bleeding, and malignancy development increase
Solution Approach 1:
The patent extracts and utilizes only the mitochondrial component from stem cells, separating it from the harmful cellular components (nucleus, cytoplasm). By using isolated mitochondria, the therapy achieves angiogenesis without the risks associated with whole stem cell transplantation, such as inflammation, bleeding, and malignancy development.
Solution Approach 2:
The patent employs mitochondria as a temporary, non-permanent therapeutic agent. The mitochondria are administered as a functional component that performs its angiogenic function and then degrades, leaving no persistent cellular material that could cause long-term harmful effects. This approach eliminates the need for long-term monitoring of stem cell-derived complications.
2Productivity
If bone marrow extraction is performed for stem cell therapy, then angiogenesis is stimulated, but adverse effects from the extraction procedure increase
Solution Approach 1:
The patent extracts mitochondria from bone marrow or peripheral blood sources, separating the useful mitochondrial component from the rest of the cellular material. This allows angiogenesis stimulation without requiring complete bone marrow extraction or stem cell transplantation, thereby eliminating the adverse effects associated with the extraction procedure.
Solution Approach 2:
The patent uses isolated mitochondria as an intermediary substance that mediates the angiogenic effect without requiring direct manipulation of bone marrow or stem cells. The mitochondria serve as a functional bridge that achieves the therapeutic goal without the harmful side effects of the extraction and manipulation processes.
3Productivity
If autologous bone marrow or mobilized peripheral blood stem cells are used, then angiogenesis is promoted, but reduced angiogenic potential occurs in aged patients with cardiovascular risk factors
Solution Approach 1:
The patent extracts and purifies mitochondria from the patient's own blood or bone marrow, creating a concentrated functional preparation that is independent of the patient's age or cardiovascular risk factors. This extracted mitochondrial preparation maintains its angiogenic function regardless of the donor's age, thereby improving reliability in aged patients.
Solution Approach 2:
The patent changes the functional parameters of the therapeutic agent by using isolated mitochondria instead of whole stem cells. This parameter change allows the therapeutic material to maintain its angiogenic activity independent of the donor's age, as the mitochondria's functional properties are preserved during isolation and do not degrade with the donor's aging process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mitochondrial composition effectively promotes the formation of new blood vessels, improving blood flow and treating ischemic conditions, while being safe and efficient, potentially reducing the need for invasive procedures like amputation and bypass surgery.
Implementation Method 1
The present invention provides compositions and methods for inducing angiogenesis in a tissue via administration of a composition comprising isolated or at least partially purified intact mitochondria and/or ruptured mitochondria derived therefrom
Implementation Method 2
partially purified intact mitochondria and/or ruptured mitochondria derived therefrom, wherein said partially purified intact mitochondria have undergone at least one freeze-thaw cycle
Data Source
AI summary
The present invention relates to compositions and methods of inducing angiogenesis and methods of treating a pathology that would benefit from angiogenesis by use of a composition comprising partially purified intact mitochondria and/or ruptured mitochondria derived therefrom.